{'fraction_non_alphanumeric': 0.015060240963855422, 'fraction_numerical': 0.004518072289156626, 'mean_word_length': 5.456310679611651, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Multimodality Treatment of Stage IIIA and IIIB Non-small Cell Lung Cancer

Stage III non-small cell lung cancer is a very heterogeneous group of patients. Principally, these patient subgroups span from minimal N2 disease stage IIIA to locally far advanced T4 tumors or multiple positive contralateral N3 lymph nodes, both considered to be stage IIIB disease. Therefore, some patient subsets are considered potentially operable after induction therapy, and others are found to be definitely inoperable. Further heterogeneity derives from multiple comorbidities of the patients and has considerable influence on the overall treatment plan in each individual patient.